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SPECIAL ARTICLE: MUSCLE AND BONE IN THE RHEUMATIC DISEASES

Incident Vertebral Fractures Among Children
With Rheumatic Disorders 12 Months After
Glucocorticoid Initiation: A National
Observational Study
CELIA RODD,1 BIANCA LANG,2 TIMOTHY RAMSAY,3 NATHALIE ALOS,4 ADAM M. HUBER,2
DAVID A. CABRAL,5 ROSIE SCUCCIMARRI,1 PAIVI M. MIETTUNEN,6 JOHANNES ROTH,3
STEPHANIE A. ATKINSON,7 ROBERT COUCH,8 ELIZABETH A. CUMMINGS,2 PETER B. DENT,7
JANET ELLSWORTH,8 JOHN HAY,9 KRISTIN HOUGHTON,5 ROMAN JURENCAK,3 MAGGIE LARCHÉ,7
CLAIRE LEBLANC,8 KIEM OEN,10 CLAIRE SAINT-CYR,4 ROBERT STEIN,11 DAVID STEPHURE,6
SHAYNE TABACK,10 BRIAN LENTLE,5 MARYANN MATZINGER,3 NAZIH SHENOUDA,3
DAVID MOHER,3 FRANK RAUCH,1 KERRY SIMINOSKI,8 LEANNE M. WARD,3
AND THE CANADIAN STEROID-ASSOCIATED OSTEOPOROSIS IN THE PEDIATRIC POPULATION
(STOPP) CONSORTIUM

Objective. To determine the frequency of incident vertebral fractures (IVF) 12 months after glucocorticoid (GC) initiation
in children with rheumatic diseases and to identify children at higher risk.
Methods. Children with rheumatic diseases initiating GC were enrolled in a prospective observational study. Annual
spine radiographs were evaluated using the Genant semiquantitative method. Spine areal bone mineral density (aBMD)
was measured every 6 months. Clinical features, including cumulative GC dose, back pain, disease and physical activity,
calcium and vitamin D intake, and spine aBMD Z scores, were analyzed for association with IVF.
Results. Seven (6%) of 118 children (95% conﬁdence interval 2.9 –11.7%) had IVF. Their diagnoses were: juvenile
dermatomyositis (n ⴝ 2), systemic lupus erythematosus (n ⴝ 3), systemic vasculitis (n ⴝ 1), and mixed connective tissue
disease (n ⴝ 1). One child was omitted from the analyses after 4 months because of osteoporosis treatment for
symptomatic IVF. Children with IVF received on average 50% more GC than those without (P ⴝ 0.030), had a greater
increase in body mass index (BMI) at 6 months (P ⴝ 0.010), and had greater decrements in spine aBMD Z scores in the
ﬁrst 6 months (P ⴝ 0.048). Four (67%) of 6 children with IVF and data to 12 months had spine aBMD Z scores less than
ⴚ2.0 at 12 months compared to 16% of children without IVF (P ⴝ 0.011).
Conclusion. The incidence of VF 12 months following GC initiation was 6%; most children were asymptomatic. Children
with IVF received more GC, had greater increases in BMI, and had greater declines in spine aBMD Z scores in the ﬁrst
6 months.

Compromised bone strength is increasingly recognized as
an important consequence of childhood rheumatic diseases. Such patients have multiple risk factors for im-

paired skeletal health, including the inﬂammatory process
itself, delayed growth and development, decreased weight
bearing and physical activity, muscle dysfunction, suboptimal nutritional status, and medications, especially glucocorticoids (GC) (1–3).
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Signiﬁcance & Innovations
●

This prospective pediatric study provides novel
insights into the timing and nature of spine fragility following glucocorticoid initiation in children
with rheumatic diseases.

●

A subset of children with rheumatic conditions
has the potential to develop incident vertebral
fractures within 12 months of glucocorticoid initiation; those who did typically manifested a single
asymptomatic incident vertebral fracture.

●

One child developed multiple painful incident
vertebral fractures 4 months following glucocorticoid initiation, prompting intervention with an
intravenous bisphosphonate.

●

Children with incident vertebral fractures tended
to receive higher doses of glucocorticoid therapy,
particularly in the ﬁrst 6 months of treatment, and
also had greater increases in body mass index Z
scores and declines in lumbar spine areal bone
mineral density Z scores.

A number of studies have documented bone mass reductions in children with rheumatic diseases (1–7). These
decrements in bone mass may increase the risk of fractures
in childhood, and potentially later in adulthood, as a result of suboptimal accrual of peak bone mass (3,4). More
deﬁnitive evidence of bone fragility in children with rheumatic diseases is provided by studies documenting vertebral and extremity fractures. Studies have reported vertebral fracture (VF) prevalence of 10 –34% (6,8 –12).
Although these ﬁndings help to establish the magnitude of
this problem during the course of the illness, clinically
relevant questions remain unanswered regarding the frequency and timing of an atraumatic incident (i.e., new) VF
(IVF) in relation to GC dose and duration.
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Through our national observational study of SteroidAssociated Osteoporosis in the Pediatric Population
(STOPP), we have prospectively studied a cohort of children with GC-treated rheumatic diseases. We have previously documented a VF prevalence of 7% in our cohort
within 30 days of GC initiation (2). The aims of the present
study were to determine the frequency and characteristics
of IVF 12 months after GC initiation and to identify patients at higher risk of fractures.

PATIENTS AND METHODS
Patients and study design. Patients were recruited
through the STOPP research initiative. Children from age 1
month to 17 years were enrolled (n ⫽ 136) between January 1, 2005, and December 31, 2007, in 10 participating
Canadian children’s hospitals. Children were enrolled
within 30 days of ﬁrst-time GC treatment for inﬂammatory
rheumatic disorders and grouped according to “related”
disease categories, as follows: juvenile dermatomyositis
(DM), systemic lupus erythematosus (SLE), and related
conditions, including mixed connective tissue disease and
other overlap syndromes, juvenile idiopathic arthritis (JIA;
excluding systemic arthritis), systemic arthritis, systemic
vasculitis (excluding Henoch-Schönlein purpura and Kawasaki disease), and “other conditions,” including juvenile scleroderma (both systemic and localized).
Children were excluded from the study if GC had previously been used for treatment of the underlying disease.
Patients were also excluded if they received intravenous or
oral GC for more than 14 consecutive days in the 12
months preceding study enrollment to treat any other
medical condition (e.g., asthma), if they received prior
medication for osteoporosis, or if they had received calcium or vitamin D supplementation that exceeded the
Dietary Reference Intake for age recommended at the time
of the study (13,14). In addition, patients who developed
symptomatic IVF during the observation period requiring
osteoporosis treatment in accordance with the local standard of care were removed from the bone health natural
history analyses from the time of osteoporosis intervention
forward (with results presented separately). Finally, children who did not have spine radiograph data at 12 months
were excluded. The clinical characteristics at study entry
were compared for children with and without 12-month
spine radiograph data.
Children were studied every 3 months for 1 year to allow
accurate collection of the clinical data. The 12-month visit
had a ⫾3-month window of time in which to collect the
data. Each participating institution’s research ethics board
approved the study, and informed consent/assent was obtained prior to enrolment.
Clinical data. Demographic and puberty data were obtained as previously described (2). Height, weight, and
body mass index (BMI; weight [kg] divided by height [meters] squared) raw values were transformed into age- and
sex-matched Z scores according to the US Centers for
Disease Control and Prevention National Center for Health
Statistics normative database (15); for children under 2
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years of age, BMI Z scores were calculated according to the
World Health Organization child growth standards (16). In
addition, the children were assessed every 3 months for
the presence of back pain since the last visit, calcium and
vitamin D intake was assessed by a validated food frequency questionnaire, and supplemental calcium and vitamin D intake was also recorded (14). Physical activity
was assessed quarterly using the Habitual Activity Estimation Scale (2,17). Additionally, a physician global assessment of disease activity was determined quarterly on a
10-cm visual analog scale (VAS) by the patients’ attending
rheumatologists (where 0 cm ⫽ inactive disease and 10
cm ⫽ extremely active disease), as previously described
(2,18 –20). At 12 months, the spine was palpated for tenderness over the posterior spinous processes (T4 to L4)
and history of back trauma was recorded.
Quantiﬁcation of GC and methotrexate exposure. Each
patient was seen quarterly to collect height and weight to
determine body surface area (calculated as the average
over the observation period) and records of all GC received. From this, the dose of systemic GC therapy (oral
and intravenous, including pulse therapy) was converted
into prednisone equivalents and results were expressed in
3 ways (21–23): 1) cumulative GC dose, deﬁned as the total
amount of GC in prednisone equivalents (mg/m2) received
during the observation period; 2) GC dose intensity, deﬁned as the cumulative dose in prednisone equivalents
(mg/m2) divided by the number of days actually taking GC
during the observation period; and 3) average GC dose,
deﬁned as the cumulative dose in prednisone equivalents
(mg/m2) divided by the total number of days in the observation period. Methotrexate exposure was expressed as
whether children had received the drug or not and as a
cumulative dose to the 12-month followup.
VF assessment. Lateral thoracolumbar spine radiographs were carried out at enrollment and 12 months. The
Genant semiquantitative method for vertebral morphometry (24) was performed as previously described (2). Vertebral bodies were ﬁrst assigned a severity score: grade 0
(normal), grade 1 (mild), grade 2 (moderate), or grade 3
(severe). The morphometric grading corresponded to the
extent of the reduction in height ratios when the anterior
vertebral height was compared to the posterior height (anterior wedge fracture), the middle height to the posterior
height (biconcave fracture), and the posterior height to the
posterior height of the adjacent vertebral bodies (crush
fracture). The scores corresponded to the following reductions in height ratios: grade 0 ⫽ 20% or less, grade 1 ⫽
⬎20% to 25%, grade 2 ⫽ ⬎25% to 40%, and grade 3 ⫽
⬎40%. Grade 0 was considered to be normal and higher
grades were considered to be a fracture.
An IVF was deﬁned as a new VF at 12 months in a
vertebral body that was normal at study entry, or worsening of an existing VF (progression from grade 1 or more to
a higher VF grade).
Lumbar spine (L-spine) bone mineral density (BMD) by
dual-x-ray absorptiometry. BMD was measured in the anteroposterior direction at the L-spine (L1–L4) using either
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Hologic machines (QDR 4500, 3 centers; Discovery, 2 centers; Delphi, 1 center) or Lunar Prodigy (4 centers) at study
enrollment and 6 and 12 months. Machines were crosscalibrated, as previously described (2). Data were converted to Hologic units and Z scores were generated using
the Hologic 12.4 normative database. In vivo precision for
L-spine areal BMD (aBMD) was available in 8 of 10 centers
and ranged from 0.003– 0.017 gm/cm2.
Bone age and second metacarpal morphometry. Radiographs of the left hand and wrist for bone age were read
independently and second metacarpal morphometry was
obtained and analyzed using the methods previously described (2).
Statistical analyses. All analyses were conducted using
SPSS, version 18.0. Categorical variables were summarized using the frequency and percentage. Normally distributed continuous variables were summarized using the
mean ⫾ SD. Non–normally distributed continuous variables were summarized using the median and range. The
95% conﬁdence intervals (95% CIs) for the proportion of
patients with vertebral deformities were calculated using
the Wilson score method (25). Z score variables were compared against the healthy average (Z score 0.0) using
1-sample Student’s t-test to assess whether the patient
population signiﬁcantly differed from the normal reference values. Results for height, weight, BMI, L-spine
aBMD, and disease activity by VAS were compared using
paired Student’s t-test at the time of study enrollment and
12 months. Children with IVF were compared to those
without using Wilcoxon-Mann-Whitney and Fisher’s exact
tests. Presented P values are 2-sided and a P value less
than or equal to 0.05 was considered signiﬁcant.

RESULTS
Characteristics of the natural history cohort. A total of
117 (86%) of the 136 children who were enrolled within
30 days of GC initiation completed the bone health natural
history assessment through to 12 months. One additional
child was included in the natural history analyses to 3
months, but was excluded thereafter because she received
osteoporosis therapy (intravenous pamidronate) for symptomatic IVF at 4 months post–GC initiation; this child is
described separately at the end of the Results. Eighteen
other children were excluded from all analyses: 10 did not
have spine radiographs at 12 months, 2 were lost to followup, and 6 withdrew consent. At study enrollment, the
clinical characteristics of these 18 children did not differ
signiﬁcantly from the natural history cohort (data not
shown).
Clinical features of the cohort at 12 months are shown in
Table 1. The characteristics of the 12-month cohort did not
differ signiﬁcantly from the full cohort at study entry with
respect to sex, ethnicity, concordance between bone age
and chronologic age, and distribution of prepubertal to
pubertal Tanner stages (data not shown). Rheumatic disease activity as measured by the 10-cm VAS showed a

Juvenile DM
(n ⴝ 27)

3 (16)
16 (84)
14.5 (5.8–17.0)
0.4 (0.0–5.9)
385 (354–596)

7 (33)
14 (67)
13.4 (3.8–17.0)
1.3 (0.0–3.0)
413 (357–3,408)

17 (6–42)

7 (1–705)

20 (91)

2 (10)

0 (0–414)

16 ⫾ 9

4⫾3

620 (0–1,527)

6,422 ⫾ 3,441

378 (167–446)

129 (4–454)
1,554 ⫾ 1,206

393 ⫾ 26

3 (15) (5.2–36.0)

390 ⫾ 23

0 (0) (0–14.9)

⫺0.4 ⫾ 1.1
2 (10)

⫺0.3 ⫾ 0.8
0.5 ⫾ 1.2
0.8 ⫾ 1.0

⫺0.4 ⫾ 1.0
0.1 ⫾ 1.5
0.3 ⫾ 1.5

⫺0.5 ⫾ 1.2
1 (5)

17 (85)
14.5 (6.0–17.2)
9 (45)

SLE and related
conditions
(n ⴝ 20)

14 (64)
13.1 (4.7–17.9)
19 (86)

JIA
(n ⴝ 22)

13 (62)

253 (0–2,977)

15 (3–58)

15 ⫾ 14

5,677 ⫾ 5,213

362 (70–442)

386 ⫾ 31

0 (0) (0–15.5)

⫺0.8 ⫾ 1.2
4 (20)

385 (343–512)

0.2 (0.0–6.3)

15 (75)
5 (25)
6.0 (1.8–17.0)

⫺0.2 ⫾ 0.9
0.5 ⫾ 1.0
0.8 ⫾ 1.2

12 (57)
6.6 (2.3–16.2)
18 (86)

Systemic
arthritis
(n ⴝ 21)

3 (19)

0 (0–565)

21 (9–33)

18 ⫾ 7

6,824 ⫾ 2,480

367 (206–419)

386 ⫾ 19

1 (6) (1.1–28.3)

⫺1.3 ⫾ 1.2
4 (27)

389 (358–459)

0.4 (0.0–5.5)

5 (36)
9 (64)
14.3 (4.2–18.0)

0.1 ⫾ 1.0
1.0 ⫾ 1.4
1.0 ⫾ 1.3

8 (50)
14.1 (5.5–17.9)
11 (69)

Systemic
vasculitis
(n ⴝ 16)

10 (91)

936 (0–1,594)

54 (8–921)

18 ⫾ 11

7,021 ⫾ 4,502

75 (9–258)

387 ⫾ 23

0 (0) (0–25.9)

0.0 ⫾ 1.0
0 (0)

444 (370–2,321)

1.1 (0.0–2.2)

6 (67)
3 (33)
8.8 (4.0–18.0)

0.2 ⫾ 0.9
0.4 ⫾ 0.9
0.5 ⫾ 0.9

7 (64)
9.0 (4.4–17.5)
11 (100)

Other
conditions
(n ⴝ 11)

* GC ⫽ glucocorticoid; DM ⫽ dermatomyositis; JIA ⫽ juvenile idiopathic arthritis (excluding systemic arthritis); SLE ⫽ systemic lupus erythematosus; BMI ⫽ body mass index; VAS ⫽ visual analog
scale; L-spine ⫽ lumbar spine; aBMD ⫽ areal bone mineral density; 95% CI ⫽ 95% conﬁdence interval; MTX ⫽ methotrexate.
† Signiﬁcantly different compared to normative reference data (Z score of 0).

Demographic data
Female, no. (%)
74 (63)
16 (59)
Age, median (range) years
11.0 (2.3–17.9)
8.3 (2.8–16.0)
White ethnicity, no. (%)
92 (79)
24 (89)
Anthropometry
Height Z score, mean ⫾ SD
⫺0.2 ⫾ 0.9†
⫺0.4 ⫾ 0.9
Weight Z score, mean ⫾ SD
0.4 ⫾ 1.3†
0.2 ⫾ 1.4
BMI Z score, mean ⫾ SD
0.7 ⫾ 1.2†
0.7 ⫾ 1.2
Pubertal stage, no. (%)
Stage 1
51 (48)
15 (65)
Stage 2–5
55 (52)
8 (35)
Bone age, median (range) years
10.8 (1.8–18.0)
7.2 (1.8–16.8)
Rheumatic disease activity
Disease activity (10-cm VAS),
0.5 (0.0–6.3)
0.2 (0.0–3.4)
median (range)
Days since diagnosis, median
393 (343–3,408)
386 (344–714)
(range)
L-spine aBMD
L-spine aBMD Z score, mean ⫾ SD ⫺0.8 ⫾ 1.2†
⫺1.5 ⫾ 1.1
L-spine aBMD Z score less than
21 (19)
10 (39)
⫺2.0, no. (%)
Vertebral fractures
Patients with incident vertebral
6 (5) (2.4–10.7)
2 (7) (2.1–23.4)
fracture, no. (%) (95% CI)
GC treatment
Days between GC initiation and
389 ⫾ 25
391 ⫾ 26
12-month spine radiograph,
mean ⫾ SD
Days in receipt of GC, median
342 (4–454)
368 (93–444)
(range)
Cumulative GC dose, mean ⫾ SD
6,369 ⫾ 5,146
10,258 ⫾ 6,330
mg/m2
16 ⫾ 13
26 ⫾ 16
Average GC dosage, mean ⫾ SD
mg/m2/day
GC dose intensity, median (range)
17 (1–921)
23 (8–71)
mg/m2/day
MTX treatment
Cumulative MTX dose, median
470 (0–2,977)
796 (0–1,426)
(range) mg/m2
Patients who received any MTX,
74 (63)
26 (96)
no. (%)

Clinical characteristics
at 12 months

Overall study
cohort with
data to 12
months
(n ⴝ 117)

Table 1. Description of children with rheumatic disorders and bone health natural history data to 12 months post–GC initiation*
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Figure 1. Mean Z scores for height, weight, body mass index
(BMI), and lumbar spine (LS) areal bone mineral density (aBMD)
at study entry and 12 months.

decrease at 12 months (median 0.5 cm, range 0 – 6.3) compared with study enrollment (median 6.3, range 0 –10.0;
P ⬍ 0.001). Compared to enrollment, height Z scores at 12
months were lower and weight Z scores were higher, resulting in increased BMI Z scores (Figure 1); these Z scores
at 12 months were all signiﬁcantly different compared to
the normative reference data (Table 1).
IVF. Of the 117 children with natural history data to 12
months post–GC initiation, 6 (5%; 95% CI 2.4 –10.7%) had
a total of 7 IVF (median age 10.9 years, range 8.4 –17.2
years, n ⫽ 4 girls). Five children had a single IVF and 1 had
2 IVF. All of the IVF were new fractures in previously
normal vertebral bodies with no signiﬁcant back trauma
having occurred in any of the children. None of the children with prevalent VF at enrollment developed IVF. Only
children with juvenile DM, SLE, and systemic vasculitis
developed IVF (Table 1). Three children (50%) had mild
(grade 1) fractures as the worst grade and 50% had moderate fractures. Five fractures (71%) were thoracic and 2

were lumbar; 6 of 7 IVF were anterior wedge fractures.
Examples of IVF that were representative of those seen at
12 months are shown in Figure 2.
Comparisons of the clinical characteristics between children with and without IVF in the natural history cohort are
shown in Tables 2 and 3. There was no difference between
the 2 groups for age, sex, pubertal status, or disease activity. Both groups had similarly low measures of disease
activity at 12 months according to the VAS (P ⫽ 0.253) and
few had back pain by self-report or by palpation, regardless of their IVF status over the 12-month period. Speciﬁcally, 37% of those without fractures reported back pain
versus 33% of children with IVF (P ⫽ 1.00). No differences
existed in second metacarpal morphometry, physical activity, or calcium and vitamin D intake (data not shown).
Analysis of GC exposure demonstrated that those with
IVF received, on average, 50% more steroids compared to
those without fractures as assessed by cumulative
(P ⫽ 0.030) or average (P ⫽ 0.044) GC dose, and nearly
double as assessed by GC dose intensity (P ⫽ 0.166) (Table
2). The greater GC exposure in those with IVF occurred
primarily in the ﬁrst 6 months of treatment, as shown in
Table 3. Those with IVF gained more weight resulting in a
higher BMI, especially at 6 months (P ⫽ 0.010); this difference disappeared by 12 months. Additionally, children
with IVF had a greater decline in L-spine aBMD Z score in
the ﬁrst 6 months of GC therapy (P ⫽ 0.048) (Table 2).
L-spine aBMD. A modest decrease in the L-spine aBMD
Z score for the entire cohort at the 12-month followup is
shown in Table 1 and Figure 1 (P ⬍ 0.001 compared to
study entry and also to the healthy average). Low bone
mass for chronologic age, deﬁned as an L-spine aBMD Z
score of less than ⫺2.0 (26), was found in 19% of patients
at 12 months and in 67% of those with IVF (Tables 1 and
2) compared to 16% of those without (P ⫽ 0.011). aBMD Z
scores below 0 (the mean for chronological age) at 12
months were present in all of the children with IVF and

Figure 2. Examples of incident vertebral fracture at 12 months. A (I) shows a normal
spine radiograph at study entry (within 30 days of glucocorticoid initiation) in an
11-year-old girl with systemic lupus erythematosus. At 12 months (II), this child
manifested a grade 1 incident vertebral fracture at L1. B (I) shows a normal spine
radiograph at study entry in a 16-year-old girl with systemic lupus erythematosus. At
12 months (II), this child was identiﬁed as having a grade 2 incident vertebral fracture
at T11.
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Table 2. Comparison of children with and without incident fractures at 12 months post–initiation of GC*

Clinical characteristics
Demographic data
Female, no. (%)
Age at 12 months, median (range) years
Anthropometry
Height Z score at 12 months, mean ⫾ SD
⌬height Z score, study entry to 6 months, mean ⫾ SD
⌬height Z score, 6 to 12 months, mean ⫾ SD
Weight Z score at 12 months, mean ⫾ SD
⌬weight Z score, study entry to 6 months, mean ⫾ SD
⌬weight Z score, 6 to 12 months, mean ⫾ SD
BMI Z score at 12 months, mean ⫾ SD
⌬BMI Z score, study entry to 6 months, mean ⫾ SD
⌬BMI Z score, 6 to 12 months, mean ⫾ SD
Pubertal stage at 12 months (Tanner stage 1), no. (%)
Bone age, median (range) years
Rheumatic disease characteristics, median (range)
VAS score at 12 months
⌬VAS score, study entry to 6 months
⌬VAS score, 6 to 12 months
Days since diagnosis
L-spine aBMD
L-spine aBMD Z score at 12 months, mean ⫾ SD
⌬L-spine aBMD Z score, study entry to 6 months, mean ⫾ SD
⌬L-spine aBMD Z score, 6 to 12 months, mean ⫾ SD
L-spine aBMD Z score less than ⫺2.0 at 12 months, no. (%)
Vertebral fractures at study entry
Patients with vertebral fractures at study entry, no. (%)
Back pain
Back pain during 12 months of followup anytime after study
entry, no. (%)
Patients with spine pain by palpation at 12 months, no. (%)
GC treatment
Days between GC initiation and 12-month spine radiograph,
mean ⫾ SD
Days in receipt of steroids, median (range)
Cumulative GC dose, mean ⫾ SD mg/m2
Average GC dosage, mean ⫾ SD mg/m2/day
GC dose intensity, median (range) mg/m2/day
MTX treatment
Cumulative MTX dose, median (range) mg/m2
Patients who received any MTX, no. (%)

Children without incident
vertebral fractures
(n ⴝ 111)

Children with incident
vertebral fractures
(n ⴝ 6)

70 (63)
11.0 (2.3 to 17.9)

4 (67)
10.9 (8.4 to 17.2)

1.000‡
0.578

⫺0.2 ⫾ 0.9
⫺0.2 ⫾ 0.7
⫺0.1 ⫾ 0.4
0.4 ⫾ 1.3
0.3 ⫾ 0.6
⫺0.2 ⫾ 0.4
0.7 ⫾ 1.2
0.5 ⫾ 0.8
⫺0.3 ⫾ 0.5
50 (50)
10.8 (1.8 to 18.0)

⫺0.3 ⫾ 0.5
⫺0.2 ⫾ 0.2
0.0 ⫾ 0.3
0.4 ⫾ 0.8
1.1 ⫾ 0.7
⫺0.6 ⫾ 0.6
0.7 ⫾ 0.8
1.4 ⫾ 0.8
⫺0.7 ⫾ 0.7
1 (20)
10.0 (7.0 to 17.0)

0.863
0.879
0.949
0.911
0.009§
0.056
0.951
0.010§
0.205
0.365‡
0.822

0.5 (0.0 to 6.3)
⫺4.4 (⫺9.6 to 3.0)
⫺0.2 (⫺4.9 to 5.8)
393 (343 to 3,408)

0.0 (0.0 to 2.2)
⫺2.5 (⫺7.6 to 1.9)
⫺0.2 (⫺1.7 to 0.0)
409 (362 to 447)

0.253
0.182
0.978
0.528

⫺0.8 ⫾ 1.2
⫺0.4 ⫾ 0.5
0.1 ⫾ 0.4
17 (16)

⫺1.7 ⫾ 1.1
⫺0.8 ⫾ 0.5
0.3 ⫾ 0.6
4 (67)

0.060
0.048§
0.674
0.011§

9 (8)

0 (0)

1.000‡

41 (37)

2 (33)

1.000‡

4 (4)

1 (20)

0.192‡

388 ⫾ 25

406 ⫾ 27

0.073

342 (4 to 454)
6,203 ⫾ 5,181
16 ⫾ 13
16 (1 to 921)

383 (264 to 446)
9,452 ⫾ 3,447
24 ⫾ 9
30 (7 to 34)

0.088
0.030§
0.044§
0.166

503 (0 to 2,977)
71 (64)

158 (0 to 1,111)
3 (50)

0.560
0.668‡

P†

* GC ⫽ glucocorticoid; BMI ⫽ body mass index; VAS ⫽ visual analog scale; L-spine ⫽ lumbar spine; aBMD⫽ areal bone mineral density; MTX ⫽
methotrexate.
† Statistical signiﬁcance determined by Mann-Whitney U test for independent samples.
‡ Statistical signiﬁcance determined by Fisher’s exact test.
§ Statistically signiﬁcant at P ⱕ 0.05.

78% of those without IVF. Two of 6 children with IVF
showed an increase in L-spine aBMD Z score from baseline
to 12 months; this was similar to the 34% of children
without IVF who had a rise in L-spine aBMD Z scores.
Patient with multiple VF requiring bisphosphonate
therapy. When the patient treated with intravenous
pamidronate was considered along with the children in
the natural history cohort, the IVF rate was 6% (95% CI
2.9 –11.7%). This 7-year-old girl with mixed connective
tissue disease developed multiple symptomatic IVF 4
months post–GC initiation (Figure 3). At enrollment her

spine radiograph was normal and her L-spine aBMD Z
score was ⫺1.1. Analysis of her bone health natural history data to 3 months demonstrated GC exposure very
similar to the other 6 children with IVF (cumulative GC
dose to 3 months was 6,838 mg/m2 in this patient versus
7,186 mg/m2 [range 1,613–9,224] for the other children
with IVF and 3,466 mg/m2 [range 14.8 –19,349] for patients
without IVF). She did not differ signiﬁcantly from the
natural history cohort with respect to calcium and vitamin
D intake, disease activity, or physical activity. Notable
clinical features of this patient included a dramatic increase in her BMI from baseline to 3 months (⌬BMI Z score
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Table 3. Distribution of glucocorticoid (GC) and methotrexate (MTX) exposure for children with and without incident
vertebral fractures during the 12-month followup period
0–6 months

Parameters
GC quantiﬁcation
Days between GC initiation
and 12-month spine
radiograph, mean ⫾ SD
Days in receipt of GC,
median (range)
Cumulative GC dose,
median (range) mg/m2
Average GC dosage,
median (range) mg/m2/
day
GC dose intensity, median
(range) mg/m2/day
MTX quantiﬁcation
Cumulative MTX dose,
median (range) mg/m2
Patients who received any
MTX, no. (%)

Children without
incident vertebral
fractures

6–12 months

Children with
incident vertebral
fractures

P*

Children without
incident vertebral
fractures

Children with
incident vertebral
fractures

P*

201 ⫾ 21

193 ⫾ 13

0.311

187 ⫾ 29

212 ⫾ 21

0.024†

182 (4–245)

192 (176–209)

0.233

168 (1–252)

199 (56–237)

0.226

4,570 (15–25,525)8,450 (2,079–10,864) 0.025†

1,156 (14–13,006)

1,291 (229–4,804) 0.904

21 (0.1–123)

43 (10–60)

0.026†

6 (0.1–64)

6 (1–21)

0.694

23 (1–922)

43 (10–60)

0.093

7 (1–903)

7 (2–21)

0.628

236 (0–1,007)

107 (0–508)

0.673

270 (0–2,608)

52 (0–611)

0.558

3 (50)

0.683‡

67 (60)

69 (62)

3 (50)

0.674‡

* Statistical signiﬁcance determined by Mann-Whitney U test for independent samples.
† Statistically signiﬁcant at P ⱕ 0.05.
‡ Statistical signiﬁcance determined by Fisher’s exact test.

3.1 versus mean ⫾ SD 1.1 ⫾ 0.4 for IVF patients and 0.6 ⫾
0.7 for children without IVF), as well as the development
of marked cushingoid features.

DISCUSSION

Figure 3. Spine radiographs from a 7-year-old girl with mixed
connective tissue disease. At study entry (A), her spine radiograph showed no signs of vertebral fractures; however, she manifested multiple painful vertebral fractures during the observation
period (B). This patient was excluded from the bone health natural history analyses because she required bisphosphonate therapy to treat the symptomatic fractures; however, a brief description of her skeletal phenotype is provided in the Results.

Prospective longitudinal data on bone health outcomes in
children with rheumatic diseases are scant, although
cross-sectional studies have demonstrated reduced bone
mass as well as fragility fractures in this population (4 –
6,8 –12,27). Our study provides novel insights into the
pace and nature of spine fragility in children with rheumatic disorders treated with GC. The 6% VF incidence
was calculated using the standard adult deﬁnition of an
IVF, with the patient as the study unit, not the individual
vertebrae (28). This deﬁnition established a priori included both de novo as well as worsening of existing VF,
since prior VF has been associated with the risk for IVF
(29); however, it is not known whether this is the case in
children. Incidentally, all of the IVF detected in our cohort
were de novo fractures, whereas none were worsening of
existing fractures and so this particular risk factor could
not be explored. Ongoing followup of our cohort will
allow us to assess whether the number of children with
IVF will indeed increase over time and whether previous
fractures will predict future fractures in children.
There was an excellent retention rate (86%) of children
in this cohort. When we examined disease subgroups, we
found IVF rates of 7% (95% CI 2.1–23.4) in juvenile DM,
15% (95% CI 5.2–36.0) in SLE, and 6% (95% CI 1.0 –28.3)
in systemic vasculitis. Several other reports concur that
children with fractures typically have more severe under-
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lying diagnoses such as SLE, juvenile DM, systemic JIA, or
systemic vasculitis (8,9). The relative contributions of systemic inﬂammation severity, the need for high-dose GC,
and other potential risk factors for poor bone health remain undetermined in these disease groups (1,7–10).
Other publications, based largely on cross-sectional analyses, cite pediatric VF rates ranging from 10 –34% in
rheumatic disorders (6,8 –12). These studies had higher VF
rates than we found in our cohort, likely because of their
longer period of followup, usually approximately 5 years,
as well as selection bias with continued followup of children with more severe disease and evaluation of symptomatic children. Previous studies have also reported higher
rates of fracture per child, one study with an average of 2.9
fractures per child (8) and one with an average of 3.3
fractures per child (9). Varonos et al (9) conducted a retrospective study of 23 children with GC-treated JIA (including 19 with systemic arthritis) who had at least 1 VF
and compared these patients to similar-aged children with
JIA also treated with GC but who had no history of VF. In
this study, the mean time from starting GC to vertebral
collapse, as documented on routine yearly spine radiographs, was 2.7 years (range 8 months to 5.5 years). Only
one-quarter of children who developed VF did so within 1
year of starting GC. This suggests that our study of the IVF
rate at 12 months may have detected only those patients
with the greatest predisposition to bone fragility, manifesting as IVF early in the course of disease treatment.
The child who received bisphosphonate treatment during our study was the exception and demonstrated numerous painful IVF early in her disease course. A few similarly affected children, each with 10 fractures, have been
reported (8,9). Our patient with multiple IVF received a
similar cumulative GC dose compared to the other 6 children with 1–2 fractures each; however, she had a greater
increase in BMI in the ﬁrst 3 months of GC treatment
compared with the other 6 children with IVF. Her early
marked Cushingoid features raise the possibility of individual genetic susceptibility to GC.
The location and severity of IVF were consistent with
ﬁndings from other pediatric studies, with a bimodal
midthoracic and thoracolumbar junction distribution
(2,6,8,9). Typically, most of the burden was in the midthoracic spine and the majority of the fractures were mild to
moderate with anterior wedge morphology (2,6,8,9). A
proposed explanation for this location relates to different
mechanical forces along the spine associated with its normal kyphosis (30).
Despite the robust size of our cohort and the acquisition
of prospective longitudinal data, our ability to derive predictors of fracture risk was limited by the small number of
patients with IVF. Those with IVF received more GC in the
ﬁrst 6 months of treatment (i.e., higher GC intensity early
on), had a somewhat higher ⌬BMI at 6 months, and also
had worsening of their L-spine aBMD Z score over the
same time period. We were not able to delineate the relative contributions of disease severity or cumulative GC
dose to IVF. This is made challenging by the fact that GC
dose may be a marker of an underlying disease variable
such as the degree of systemic inﬂammation. The cumulative GC dose was strongly associated with prevalent VF
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in a study of 94 children with a variety of rheumatic
diseases followed at a single center (8). There are, however, conﬂicting reports in the literature on the correlation
of GC dose with the prevalence of VF and reduced bone
mass in children with rheumatic diseases (6,8). This may,
in part, reﬂect the heterogeneity of the disease populations
studied, as well as the varied duration of diseases and their
treatment in the various reports.
Based on observations in adults with VF, there is a
suggestion of a threshold for lower BMD predisposing to
fractures (31). Similarly, in children with rheumatic diseases, a threshold Z score was observed for volumetric
L-spine BMD of ⫺1.8 predicting fractures (11). In our
study, we noted that 67% of those with IVF had a BMD Z
score of less than ⫺2.0 compared to 16% of those without
IVF. Given the small number of children with IVF in this
study, we were unable to determine if a precise spine BMD
threshold exists.
On average we found a modest decrease in the L-spine
aBMD Z score over 12 months post–GC initiation. Data
from most longitudinal studies are not directly comparable
to ours because the commencement of their followup occurred on average 2 years following GC initiation (5,7,32).
Within the entire cohort, 19% had L-spine aBMD Z scores
of less than ⫺2.0, which has been referred to as “low bone
mass for chronologic age” in the literature (10,26). In particular, approximately one-quarter of children with juvenile DM and systemic vasculitis had an L-spine aBMD Z
score of less than ⫺2.0 at 12 months, as did approximately
20% of those with systemic JIA. Ongoing longitudinal
followup of our cohort is essential to help understand the
signiﬁcance of these spine BMD ﬁndings, particularly in
relation to IVF.
Within the IVF group, only a small number experienced
back pain or tenderness, which is consistent with previous
studies reporting that many children who experience IVF
are asymptomatic, or if symptoms are present they are
mild and may be transient (6,12). This is in direct contrast
to our cohort at enrollment, when back pain was found to
be highly associated with prevalent VF (2). Sex was not
associated with IVF, nor was the use of methotrexate. The
role of methotrexate as osteotoxic or osteoprotective has
not been determined, as there are conﬂicting reports regarding its association with IVF (8,11).
There are limitations to our study that deserve consideration. First, since back pain was only assessed on a
3-month basis, it is possible that the frequency of transient
pain may have been underestimated. Second, daily divided GC dosing was not captured, and therefore we could
not determine if the frequency of the dosing in a 24-hour
period played a role in the development of IVF (9). Moreover, we did not ascertain precise data on ancillary medications such as disease-modifying antirheumatic drugs
other than methotrexate that might have provided additional proxy data on the severity of the underlying illness.
It is also possible that the use of potent biologic agents may
have signiﬁcantly reduced the risks of IVF by the inhibition of cytokines known to promote bone resorption (33).
This cohort of children is quite heterogeneous in regard to
underlying diagnoses, potentially limiting our power to
see differences. Finally, serum 25-hydroxyvitamin D lev-
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els were not available; the deliberate rationale for excluding this parameter has been outlined previously (2).
In summary, the incidence of VF at 12 months post–GC
initiation in children with rheumatic diseases was 6% and
most children were asymptomatic. One child was more
severely affected with multiple painful fractures. Overall,
there was a suggestion that children with IVF received
more GC during the observation period and had greater
increases in BMI and declines in L-spine aBMD Z scores in
the ﬁrst 6 months of GC treatment. The longitudinal nature
of this study with further followup should provide muchneeded insights into the future risk for VF in this context.
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